Literature DB >> 19223573

Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity.

O Mir1, J Alexandre, A Tran, J-P Durand, G Pons, J-M Treluyer, F Goldwasser.   

Abstract

BACKGROUND: Glutathione-S-transferases (GST) regulate the cellular response to oxidative stress. We previously highlighted the importance of oxidative stress in taxane toxicity and therefore investigated the relationship between the GST isoforms M1, T1 and P1 gene polymorphisms and docetaxel (Taxotere)-induced peripheral neuropathy (DIPN). PATIENTS AND METHODS: The GSTM1 (null), GSTT1 (null) and GSTP1 (Ile(105)Val and Ala(114)Val) polymorphisms were determined in a cohort of cancer patients treated with docetaxel and entered in a clinical trial database. The relationship between GST polymorphisms and grade > or = 2 DIPN as primary end point was studied.
RESULTS: Fifty-eight patients (median age 61 years) received a total of 261 cycles of docetaxel given as single agent. Patients with GSTP1 (105)Ile/(105)Ile genotype had a higher risk of developing a grade > or = 2 DIPN than did those with other GSTP1 genotypes (8 of 27 versus 2 of 31, respectively, odds ratio 6.11; 95% confidence interval 1.17-31.94; P = 0.03). In multivariate analysis, grade > or = 2 DIPN was strongly correlated with GSTP1 (105)Ile/(105)Ile genotype (P = 0.01) and the number of cycles (P = 0.03).
CONCLUSION: We found a significant correlation between GSTP1 (105)Ile/(105)Ile genotype and the development of grade > or = 2 DIPN. This finding strongly suggests a role of oxidative stress in the pathophysiology of DIPN.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19223573     DOI: 10.1093/annonc/mdn698

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  29 in total

1.  Effects of gene polymorphisms on the risk of severe hyponatremia during DCF chemotherapy for patients with esophageal squamous cell carcinoma.

Authors:  Yasuhiro Arakawa; Yoshihiro Shirai; Kazumi Hayashi; Yujiro Tanaka; Akira Matsumoto; Katsunori Nishikawa; Shingo Yano
Journal:  Oncol Lett       Date:  2018-07-31       Impact factor: 2.967

2.  Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are associated with susceptibility and chemotherapy response in non-small-cell lung cancer patients.

Authors:  WeiYing Li; WenTao Yue; LiNa Zhang; XiaoTing Zhao; Li Ma; XueHui Yang; ChunYan Zhang; Yue Wang; Meng Gu
Journal:  Lung       Date:  2011-11-23       Impact factor: 2.584

3.  Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.

Authors:  Song Yao; William E Barlow; Kathy S Albain; Ji-Yeob Choi; Hua Zhao; Robert B Livingston; Warren Davis; James M Rae; I-Tien Yeh; Laura F Hutchins; Peter M Ravdin; Silvana Martino; Alan P Lyss; C Kent Osborne; Martin Abeloff; Gabriel N Hortobagyi; Daniel F Hayes; Christine B Ambrosone
Journal:  Clin Cancer Res       Date:  2010-12-15       Impact factor: 12.531

4.  Proposed medications for taxane-induced myalgia and arthralgia (Review).

Authors:  Atsushi Imai; Kazutoshi Matsunami; Hiroshi Takagi; Satoshi Ichigo
Journal:  Oncol Lett       Date:  2012-03-23       Impact factor: 2.967

5.  Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.

Authors:  Qing-Fang Li; Ru-Yong Yao; Ke-wei Liu; Hong-Ying Lv; Tao Jiang; Jun Liang
Journal:  J Korean Med Sci       Date:  2010-05-24       Impact factor: 2.153

Review 6.  Docetaxel: its role in current and future treatments for advanced gastric cancer.

Authors:  Masahiko Nishiyama; Satoru Wada
Journal:  Gastric Cancer       Date:  2009-11-05       Impact factor: 7.370

7.  Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.

Authors:  Stefanie D Krens; Howard L McLeod; Daniel L Hertz
Journal:  Pharmacogenomics       Date:  2013-04       Impact factor: 2.533

Review 8.  Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems.

Authors:  Nathan P Staff; Jill C Fehrenbacher; Martial Caillaud; M Imad Damaj; Rosalind A Segal; Sandra Rieger
Journal:  Exp Neurol       Date:  2019-11-21       Impact factor: 5.330

9.  Examination of polymorphic glutathione S-transferase (GST) genes, tobacco smoking and prostate cancer risk among men of African descent: a case-control study.

Authors:  Nicole A Lavender; Marnita L Benford; Tiva T VanCleave; Guy N Brock; Rick A Kittles; Jason H Moore; David W Hein; La Creis R Kidd
Journal:  BMC Cancer       Date:  2009-11-16       Impact factor: 4.430

10.  Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.

Authors:  Daniel L Hertz; Kouros Owzar; Sherrie Lessans; Claudia Wing; Chen Jiang; William Kevin Kelly; Jai Patel; Susan Halabi; Yoichi Furukawa; Heather E Wheeler; Alexander B Sibley; Cameron Lassiter; Lois Weisman; Dorothy Watson; Stefanie D Krens; Flora Mulkey; Cynthia L Renn; Eric J Small; Phillip G Febbo; Ivo Shterev; Deanna L Kroetz; Paula N Friedman; John F Mahoney; Michael A Carducci; Michael J Kelley; Yusuke Nakamura; Michiaki Kubo; Susan G Dorsey; M Eileen Dolan; Michael J Morris; Mark J Ratain; Howard L McLeod
Journal:  Clin Cancer Res       Date:  2016-05-03       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.